Insider Trading Alert - ANAC, SPAR And HLF Traded By Insiders

Yesterday, March 22, 2016, 62 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $393.86 to $985,495,661.49.

Highlighted Stocks Traded by Insiders:

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Berns Paul L, who is President and CEO at Anacor Pharmaceuticals, sold 37,500 shares at $60.31 on March 22, 2016. Following this transaction, the President and CEO owned 230,311 shares meaning that the stake was reduced by 14% with the 37,500-share transaction.

The shares most recently traded at $58.48, down $1.83, or 3.13% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 9,000
  • 12-Week # shares sold: 14,587
  • 24-Week # shares sold: 54,587

The average volume for Anacor Pharmaceuticals has been 955,500 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $2.7 billion and is part of the health care sector and drugs industry. Shares are down 46.93% year-to-date as of the close of trading on Tuesday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It markets KERYDIN (tavaborole) topical solution for the treatment of onychomycosis of the toenails. Currently, there are 3 analysts who rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings rates Anacor Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, generally high debt management risk and disappointing return on equity. Get the full Anacor Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Spartan Motors (SPAR) - FREE Research Report

Slawson John W, who is Pres., Spartan Emer. Response at Spartan Motors, bought 2,600 shares at $3.87 on March 22, 2016. Following this transaction, the Pres., Spartan Emer. Response owned 7,000 shares meaning that the stake was boosted by 59.09% with the 2,600-share transaction.

The shares most recently traded at $4.00, up $0.13, or 3.16% since the insider transaction. Historical insider transactions for Spartan Motors go as follows:

  • 4-Week # shares bought: 34,400
  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 34,400
  • 12-Week # shares sold: 15,000
  • 24-Week # shares bought: 34,400
  • 24-Week # shares sold: 15,000

The average volume for Spartan Motors has been 94,300 shares per day over the past 30 days. Spartan Motors has a market cap of $139.5 million and is part of the consumer goods sector and automotive industry. Shares are up 29.9% year-to-date as of the close of trading on Tuesday.

Spartan Motors, Inc., through its subsidiaries, engineers, manufactures, and sells heavy-duty and custom vehicles in the United States, Canada, South America, and Asia. The stock currently has a dividend yield of 2.52%. Currently, there are no analysts who rate Spartan Motors a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPAR - FREE

TheStreet Quant Ratings rates Spartan Motors as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, poor profit margins and feeble growth in its earnings per share. Get the full Spartan Motors Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Herbalife (HLF) - FREE Research Report

Chiu Shin-Shing Bosco, who is Principal Accounting Officer at Herbalife, sold 2,000 shares at $63.00 on March 22, 2016. Following this transaction, the Principal Accounting Officer owned 2,000 shares meaning that the stake was reduced by 50% with the 2,000-share transaction.

The shares most recently traded at $61.49, down $1.51, or 2.46% since the insider transaction. Historical insider transactions for Herbalife go as follows:

  • 4-Week # shares bought: 600
  • 4-Week # shares sold: 1,686
  • 12-Week # shares bought: 600
  • 12-Week # shares sold: 1,686
  • 24-Week # shares bought: 600
  • 24-Week # shares sold: 1,686

The average volume for Herbalife has been 2.2 million shares per day over the past 30 days. Herbalife has a market cap of $5.8 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 16.41% year-to-date as of the close of trading on Tuesday.

Herbalife Ltd., a nutrition company, develops and sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, and personal care products. The company has a P/E ratio of 19.4. Currently, there is 1 analyst who rates Herbalife a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HLF - FREE

TheStreet Quant Ratings rates Herbalife as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive. Get the full Herbalife Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

State Street Gets Pummeled on Software Deal; Pizza Wars Are Raging -- ICYMI

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

Schlumberger Stock Dips as Investors Ignore Start of 'Earnings Liftoff'

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

GSK Shares Climb as Board Is Said to Mull Breakup of Pharma Giant

Stocks End Close to Home

Stocks End Close to Home

Jim Cramer on Bank of America, Tariffs and the Goldman Sachs CEO Change

Jim Cramer on Bank of America, Tariffs and the Goldman Sachs CEO Change